1.Effect of amelogenin on the migration,adhesion and proliferation of periodontal ligament stem cells
Xi ZHAO ; Yujia HAN ; Yu XIONG
Journal of Regional Anatomy and Operative Surgery 2016;25(5):327-330
Objective To study the effect of amelogenin (AML)on the migration,adhesion and proliferation of periodontal ligament stem cells (PDLSCs).Methods STRO-1 +PDLSCs were selected by Flow cytometer.The transwell system was used to detect the effect of AML on migration of PDLSCs.Cells attachment assay was used to detect the effect of AML on adhesion of PDLSCs.MTT was used to detect the effect of AML on the proliferation of PDLSCs.Results The results of transwell showed that AML could induce the migration of PDLSCs with positive correlation.Cells attachment assay showed that the adhesion of PDLSCs was effected by AML as well,and the effect was in-creased with the extension of incubation time.Results of MTT showed that AML could promote the proliferation of PDLSCs in a dose depend-ent manner.Conclusion AML could increase the proliferation,adhesion and migration potential of PDLSCs.
2.Clinical features and prognostic factors of primary gastric neuroendocrine neoplasms
Yujia XIONG ; Xiaoyu LIU ; Cuie CHENG ; Chen CHEN ; Yibin SUN ; Chenhuan TAN ; Yiting LIU ; Ji FENG ; Yifan MA ; Dongtao SHI ; Rui LI ; Qiyun TANG
Chinese Journal of Internal Medicine 2020;59(4):297-302
Objective:To study the clinical characteristics and classification of gastric neuroendocrine neoplasm(NEN) and prognostic factors of mixed adenoneuroendocrine carcinoma (MANEC) and gastric neuroendocrine carcinoma(NEC).Methods:A total of 148 gastric NENs were divided into type Ⅰ, type Ⅱ and type Ⅲ based on the classification of European Neuroendocrine Tumor Society (ENETS). Kaplan-Meier test and Cox regression model were used in univariate and multivariate survival analysis in 108 cases with pathological G3 gastric NEN.Results:In this study, the percentages of type Ⅰ, type Ⅱ and type Ⅲ were 25.0%(37), 3.4%(5) and 71.6%(106) respectively. Among type Ⅰ patients, 28(75.7%) lesions were located in gastric fundus or body, 29(78.4%) had bumps. Lymph node involvement was found in 4 (10.8%) patients. Twenty-six (70.3%) patients received endoscopic treatment and 11 (29.7%) with surgery. All 5 type Ⅱ patients presented lesions in gastric fundus or body, including 4 with ulcers, who were all treated by endoscope. Three type Ⅱ patients had gastrinoma, and 2 combined with multiple endocrine neoplasmⅠ. In type Ⅲ patients, 56(52.8%) showed ulcerative lesions. The majority of patients (102, 96.2%) had a single lesion, 94(88.7%) with lymph node or other organ metastasis. In this study, no deaths were reported in gastric NEN with a pathological grade of G1 or G2. The mortality rate was 38.9%(42/108) in patients with G3 NEN. Survival analysis suggested that age, metastasis of tumor were associated with poor prognosis ( P=0.041, 0.025). Conclusions:Patients with gastric NEN have heterogenous clinical presentations according to gender, age, endoscopic features, infiltration and metastasis, and pathological grade. Aging and metastasis are negative prognostic factors of G3 gastric NEN.
3.Evaluation of polysaccharide hemostatic system for arterial hemorrhage of upper digestive tract
Yibin SUN ; Chen CHEN ; Yujia XIONG ; Chenhuan TAN ; Yiting LIU ; Ji FENG ; Yifan MA ; Dongtao SHI ; Deqing ZHANG ; Ling LI ; Rui LI
Chinese Journal of Digestive Endoscopy 2022;39(7):559-563
Objective:To study the efficacy and safety of EndoClot polysaccharide hemostatic system (EndoClot PHS) for heparinized arterial hemorrhage of upper digestive tract (Forrest Ⅰa) in animal model.Methods:Twelve experimental pigs were randomly divided into the test group ( n=6) and the control group ( n=6) by simple random grouping method. Gastric arterial hemorrhage models were established. Endoclot PHS and Hemospray were used to spray on the wound to stop bleeding in the test group and the control group respectively. The time of effective hemostasis, the amount of hemostatic particles used, and the blockage of the powder feeding tube and its replacement were compared between the two groups. The survival and complications of experimental pigs were observed after the operation. In 10 days after the operation, the experimental pigs were euthanized for pathological dissection. Results:Spurting or pulsatile bleeding was achieved in all experimental pigs. There were significant differences in the time of effective hemostasis (8.75±0.84 min VS 9.83±0.62 min, t=-2.53, P=0.030) and the amount of hemostatic particles used to achieve effective hemostasis (6.71±0.39 g VS 14.10±1.62 g, t=-10.86, P<0.001) between the test group and the control group. There was no significant difference in the occurence of clogging or the replacement of powder feeding pipes between the two groups (0.64±0.02 times VS 0.67±0.04 times, t=-1.64, P=0.131). In addition, the gas source of the test group was stable, and the visual field under the endoscope was clear. Neither the test group nor the control group had gastric lesions, perforation, or embolism. The blood glucose, blood routine, and liver and kidney functions were normal, and no thrombosis or embolism of the main organs occurred in either group. Conclusion:EndoClot PHS is safe and effective for heparinized upper gastrointestinal arterial hemorrhage (Forrest Ⅰa) in animal models.
4.Correlation between the mutation spectrum of the UGT1A1 gene and clinical phenotype in patients with inherited hyperunconjugated bilirubinemia
Qingfang XIONG ; Yujia LU ; Lei ZOU ; Hui ZHOU ; Hao REN ; Xiaoning FENG ; Yongfeng YANG
Chinese Journal of Hepatology 2024;32(4):340-345
Objective:To analyze the distribution characteristics of UGT1A1 mutant genes (including enhancers, promoters, and exons 1-5) and further explore the correlation between UGT1A1 genotype and clinical phenotypes in patients with inherited hyperunconjugated bilirubinemia.Methods:Patients diagnosed with hereditary hyperunconjugated bilirubinemia at Nanjing Second Hospital from June 2015 to December 2022 were retrospectively analyzed. The UGT1A1 gene was examined using Sanger sequencing in all patients. Complete blood count, liver function, and abdominal imaging examinations were performed. Comparison of categorical variable data using χ2 testor Fisher percision tests. Comparison of continaous veriable data with normal distribution using t-test. Results:112 cases (male:female ratio 81:31, aged 9-70 years) had inherited hyperunconjugated bilirubinemia, with a total of 14 mutation sites identified, of which seven were confirmed mutations, and the frequency ranged from high to low: (TA)n accounted for 50%, c.211G>A (p.G71R) accounted for 49.10%, 1456T>G (p.Y486D) accounted for 16.96%, c.686C>A (p.R229W) accounted for 12.5%, 1091C>T (p.P364L) accounted for 8.04%, and c- 3279T>G accounted for 0.982%. Simultaneously, all patients had one to four mutations, of which only one mutation was the most common (55.36%), followed by two mutations (37.5%), and rare three and four mutations (5.36% and 1.78%). There was no statistical significance in total bilirubin (TBil) levels among the four groups ( F=0.652, P=0.583). One mutation was most common in (TA)n and c.211G>A (p.G71R), among which TA6/TA7 ( n=10) and TA7/TA7 ( n=14) mutations were statistically significant in TBil ( t=2.143, P=0.043). The c.211G>A (p.G71R) heterozygous ( n=9) and isolated ( n=15) mutation had no statistical significance in TBil ( t=0.382, P=0.706). The GS group accounted for 75%, the intermediate group accounted for 16.9%, and the CNS-Ⅱ group accounted for 8%. TBil was statistically significant among the three groups ( F=270.992, P<0.001). There was no statistically significant difference ( χ2=3.317, P=0.19) between mutation 1 (44 cases, 14 cases, and 4 cases, respectively) and mutations ≥ 2 (40 cases, 5 cases, and 5 cases, respectively) in the GS group, intermediate group, and CNS-II group. Conclusion:The number of UGT1A1 gene mutation sites may have no synergistic effect on TBil levels in patients with inherited hyperunconjugated bilirubinemia. TA7/TA7 mutations are not uncommon, and TBil levels are relatively high.
5.Advances in Site-specific Conjugation Technologies Applied to the Synthesis of Antibody-Drug Conjugates
Yujia CHEN ; Ziyi YOU ; Chanyuan XIONG ; Li LIN ; Liqiang PAN
Chinese Journal of Modern Applied Pharmacy 2024;41(2):261-276
Antibody-drug conjugates(ADCs), as an emerging therapy for cancer treatment, have made significant progress in the past few decades. However, due to the heterogeneity of ADCs, they still face various issues and challenges in clinical therapy. Therefore, site-specific conjugation techniques have become a crucial area of research in ADCs, and in recent years, this field has witnessed numerous breakthrough advancements, empowering ADCs with enhanced performance. The review provides a comprehensive overview of the frontiers in site-specific conjugation technologies for ADCs. Categorized into seven major classes including lysine-based, cysteine-based, low-abundance amino acid-based and glycosylation site-based conjugation techniques, ribosomal incorporation of unnatural and noncanonical amino acids and enzyme-mediated conjugation techniques, it meticulously describes 21 classical and emerging techniques such as the THIOMAB technology and linchpin-directed modification, in order to offer valuable insights for the development of next-generation ADCs.
6.Gender differences in mortality following tanscatheter aortic valve replacement (TAVR): a single-centre retrospective analysis from China.
Qi LIU ; Yali WANG ; Yijian LI ; Tianyuan XIONG ; Fei CHEN ; Yuanweixiang OU ; Xi WANG ; Yijun YAO ; Kaiyu JIA ; Yujia LIANG ; Xin WEI ; Xi LI ; Yong PENG ; Jiafu WEI ; Sen HE ; Qiao LI ; Wei MENG ; Guo CHEN ; Wenxia ZHOU ; Mingxia ZHENG ; Xuan ZHOU ; Zhengang ZHAO ; Chen MAO ; Feng YUAN
Chinese Medical Journal 2023;136(20):2511-2513
7.Peri-procedural myocardial injury predicts poor short-term prognosis after TAVR: A single-center retrospective analysis from China.
Qi LIU ; Kaiyu JIA ; Yijun YAO ; Yijian LI ; Tianyuan XIONG ; Fei CHEN ; Yuanweixiang OU ; Xi WANG ; Yujia LIANG ; Xi LI ; Yong PENG ; Jiafu WEI ; Sen HE ; Qiao LI ; Wei MENG ; Guo CHEN ; Wenxia ZHOU ; Mingxia ZHENG ; Xuan ZHOU ; Yuan FENG ; Mao CHEN
Chinese Medical Journal 2023;136(24):3013-3015